Dr. Max Kates, MD
Urology (Urology Physician)
Johns Hopkins, 600 N Wolfe St - Tower 110
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 481
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Icahn School of Medicine at Mount Sinai
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
MD license TBD -
Surgery Physician
MD license TBD
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Beebe Medical Center Lewes, DE
- Sibley Memorial Hospital Washington, DC
Medical groups
- Johns Hopkins University (2,909 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 481
- Services billed
- 1,494
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Diagnostic exam of bladder and urethra using an endoscope | 317 | 213 |
| Simple bladder irrigation and/or instillation | 287 | 187 |
| Established patient office or other outpatient visit, 20-29 minutes | 137 | 106 |
| New patient office or other outpatient visit, 60-74 minutes | 121 | 121 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 64 | 57 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 52 | 45 |
| Destruction and/or removal of large growth of bladder using an endoscope | 38 | 36 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 32 | 32 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 28 | 28 |
| New patient office or other outpatient visit, 30-44 minutes | 25 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Baltimore, MD | 26 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Baltimore, MD | 23 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Baltimore, MD | 15 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Baltimore, MD | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 24 payments worth $76,970 in total to this clinician.
| Urogen Pharma, Inc. | $63,387 |
|---|---|
| Pfizer Inc. | $5,940 |
| Janssen Global Services, LLC | $2,600 |
| AstraZeneca Pharmaceuticals LP | $2,540 |
| Immunitybio, Inc. | $2,400 |
| Ethicon US, LLC | $77.56 |
| Merck Sharp & Dohme LLC | $25.70 |
| Consulting Fee | $72,045 |
|---|---|
| Honoraria | $2,400 |
| Travel and Lodging | $1,468 |
| Food and Beverage | $997 |
| Education | $60.76 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Urogen Pharma, Inc. Jun 4, 2025 | Consulting Fee | $27,600 |
| Urogen Pharma, Inc. Apr 4, 2025 | Consulting Fee | $14,400 |
| Urogen Pharma, Inc. Apr 4, 2025 | Consulting Fee | $11,800 |
| Urogen Pharma, Inc. Jan 16, 2025 | Consulting Fee | $7,200 |
| Pfizer Inc. Jan 13, 2025 | Consulting Fee PADCEV · ONCOLOGY | $3,840 |
| Janssen Global Services, LLC Sep 26, 2025 | Consulting Fee | $2,600 |
| AstraZeneca Pharmaceuticals LP Dec 1, 2025 | Consulting Fee IMFINZI · Oncology | $2,505 |
| Immunitybio, Inc. Jul 23, 2025 | Honoraria ANKTIVA · Immunotherapy | $2,400 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee PADCEV · ONCOLOGY | $2,100 |
| Urogen Pharma, Inc. May 21, 2025 | Travel and Lodging travel to SLIVER SPRING, MD · in-kind | $527 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 1, 2025 | Consulting Fee IMFINZI · Oncology | $2,505 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee PADCEV · ONCOLOGY | $2,100 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $35.06 |
| Janssen Global Services, LLC Sep 26, 2025 | Consulting Fee | $2,600 |
| Immunitybio, Inc. Jul 23, 2025 | Honoraria ANKTIVA · Immunotherapy | $2,400 |
| Urogen Pharma, Inc. Jun 4, 2025 | Consulting Fee | $27,600 |
| Urogen Pharma, Inc. May 21, 2025 | Travel and Lodging travel to SLIVER SPRING, MD · in-kind | $527 |
| Urogen Pharma, Inc. May 7, 2025 | Travel and Lodging travel to PHILADELPHIA, PA · in-kind | $211 |
| Merck Sharp & Dohme LLC Apr 29, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
| Urogen Pharma, Inc. Apr 14, 2025 | Travel and Lodging travel to PHILADELPHIA, PA · in-kind | $198 |
| Urogen Pharma, Inc. Apr 4, 2025 | Consulting Fee | $14,400 |
| Urogen Pharma, Inc. Apr 4, 2025 | Consulting Fee | $11,800 |
| Urogen Pharma, Inc. Mar 14, 2025 | Travel and Lodging travel to NEWARK, NJ · in-kind | $278 |
| Urogen Pharma, Inc. Mar 13, 2025 | Travel and Lodging travel to NEWARK, NJ · in-kind | $108 |
| Urogen Pharma, Inc. Feb 27, 2025 | Travel and Lodging travel to NEWARK, NJ · in-kind | $146 |
| Urogen Pharma, Inc. Jan 16, 2025 | Consulting Fee | $7,200 |
| Pfizer Inc. Jan 13, 2025 | Consulting Fee PADCEV · ONCOLOGY | $3,840 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $195,227 in research payments for these studies, mostly to the institutions running them.
- Blue Light Cystoscopy With Cysview Registry
Photocure Inc - A study of intravesical enfortumab vedotin for treatment of patients with nonmuscle invasive bladder cancer nmibc
Pfizer Inc. - ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Ferring Pharmaceuticals As · Terminated · NCT06026332
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.